Cancers of the oral cavity (OC) and oropharynx (OPC) are predominantly caused by tobacco and alcohol use, although oral infection with HPV, particularly HPV16, is an increasingly important cause of OPC[@R1], especially in the US and northern Europe[@R1],[@R2]. The proportion of HPV-related OPCs varies widely and is estimated to be approximately 60% in the US, 30% in Europe and lower in South America[@R2]--[@R5]. Genetic factors have also been implicated in OC and OPC susceptibility, especially polymorphisms within alcohol-related genes including alcohol-dehydrogenase 1B (*ADH1B*) and *ADH7*[@R6],[@R7]. In order to identify additional susceptibility loci, 13,107 individuals from 12 epidemiological studies ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}) were genotyped using the Illumina OncoArray and after stringent quality-control steps ([Supplementary Table 2](#SD14){ref-type="supplementary-material"}, [Online Methods](#S1){ref-type="sec"}) 6,034 cases and 6,585 cancer-free controls remained for analyses ([Table 1](#T1){ref-type="table"}). We next performed genome-wide imputation using the Haplotype Reference Consortium panel[@R8] and obtained approximately 7 million high-quality imputed variants ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). Given the ethnic diversity of our study, we evaluated associations within continent (Europe, North and South America) using multivariate unconditional logistic regressions under a log-additive genetic model adjusted for age, sex and regional eigenvectors. Results by continent were combined using fixed-effect meta-analyses to derive associations for overall OC and pharynx cancer (oral, oropharynx, hypopharynx and overlapping cancers; n = 6,034), as well as site-specific OC (n = 2,990) and OPC (n = 2,641). Although, several ethnic groups are present in the study, supervised ancestry analyses indicated that \>90% of participants were predominantly of European (\>70%CEU) ancestry, although some population admixture was observed in South America ([Supplementary Table 3](#SD14){ref-type="supplementary-material"}).

GWA meta-analyses of overall and site-specific cancers identified 9 regions at genome-wide significance (*P* \< 5x10^--8^) ([Fig.1](#F1){ref-type="fig"}). Quantile-quantile (Q-Q) plots of observed and expected *P-*values showed moderate genomic inflation (λ) for the 3 meta-analyses (λ range = 1.04--1.06, [Supplementary Fig. 2--3](#SD1){ref-type="supplementary-material"}). Since λ increases with sample size, we scaled it to 1000 cases and controls resulting in ameliorated inflation (λ~1000~ range = 1.009--1.01)[@R9]. Overall OC and pharynx cancer were associated with rs79767424 (5p14.3), rs1229984 (4q23), rs201982221 (10q26.13), rs1453414 (11p15.4) and 123 SNPs at 6p21.32 ([Supplementary Table 4](#SD8){ref-type="supplementary-material"}). Twenty-six variants were associated (*P* \< 5x10^--8^) with OC ([Supplementary Table 5](#SD9){ref-type="supplementary-material"}), 4 of which mapped to 2p23.3, 1 to 4q23, 3 to 9q34.12, 13 to 5p15.33 and 5 to 9p21.3. For OPC, novel significant variants were located at 6p21.32 (62 SNPs, [Supplementary Table 6](#SD10){ref-type="supplementary-material"}). Suggestive susceptibility variants (*P* \< 5x10^--7^, [Supplementary Tables 7](#SD11){ref-type="supplementary-material"}--[9](#SD13){ref-type="supplementary-material"}) were associated with OC at 4 additional loci: 6p21.33, 6p21.32, 15q21.2, 15q26.2 and, with OPC at 2q36.1. Other genomic locations outside the HLA region showed promising associations (*P* \< 5x10^--6^) with OPC ([Supplementary Table 10](#SD3){ref-type="supplementary-material"}). For susceptibility loci at *P* \< 5x10^--8^, functional annotation of regulatory features with ENCODE and eQTL information, if available, are summarized in [Supplementary Table 11](#SD4){ref-type="supplementary-material"} and [12](#SD14){ref-type="supplementary-material"}. Given the geographical heterogeneity of our population, we performed sensitivity analyses after excluding individuals with \<70% CEU ancestry and these showed similar results ([Supplementary Table 13](#SD14){ref-type="supplementary-material"}). To validate array genotypes and imputed dosages, we directly genotyped by a different platform (TaqMan) at least one variant within each locus (*P* = 5x10^--7^) in a subset of approximately 700 individuals. Concordance between genotyped/imputed genotypes and TaqMan results was \>97% for all regions with the exception of rs2398180, an imputed variant which had a concordance of 94% ([Supplementary Table 14-15](#SD14){ref-type="supplementary-material"}). For 2 rare variants, rs201982221 (10q26.13) and rs7976742 (5p14.3), TaqMan assays could not be designed and we used Sanger sequencing for validation ([Supplementary Table 16](#SD14){ref-type="supplementary-material"}). We were able to validate the rs201982221 deletion ([Online Methods](#S1){ref-type="sec"}), but rs7976742 did not validate ([Online Methods](#S1){ref-type="sec"}). The lead variant at each validated loci (*P* \< 5x10^--8^) for overall and site-specific analyses are shown in [Table 2](#T2){ref-type="table"}. Results stratified by geographical region, smoking and alcohol status are displayed in [Figure 2](#F2){ref-type="fig"} (oral and pharynx cancer combined) and [Figure 3](#F3){ref-type="fig"} (oral cancer).

The rs1229984 (4q23, *ADH1B*) association has been previously reported as a susceptibility locus for OC and OPC[@R6], and similar to previous findings this variant showed heterogeneity by region, smoking and alcohol drinking status[@R10],[@R11] ([Fig. 2a](#F2){ref-type="fig"}). Three other 4q23 SNPs reached *P* \< 5x10^--8^, although conditional analyses indicated these are not independent signals ([Supplementary Table 17](#SD14){ref-type="supplementary-material"}). The rs1573496 (*ADH7*) variant reported to be strongly associated with OC and OPC in the previous upper aerodigestive tract cancer GWAS[@R7] was only moderately associated here ([Supplementary Table 18](#SD14){ref-type="supplementary-material"}). In the overall OC and pharynx cancer analysis, we identified rs201982221 at 10q26.13 (OR = 1.67, *P* = 1.58x10^--9^), that was also separately associated with OC (OR = 1.71, *P* = 1.04x10^--7^) and OPC (OR = 1.70, *P* = 7.9x10^--7^) ([Fig. 2b](#F2){ref-type="fig"}). rs201982221 is located within the *LHPP* gene in a region with reported regulatory features ([Supplementary Table 11](#SD4){ref-type="supplementary-material"}). However, it is a rare intronic deletion in an area of low linkage disequilibrium (LD) ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}), and thus warrants further validation in a different population. rs1453414, the lead signal at 11p15.4 ([Supplementary Table 19](#SD14){ref-type="supplementary-material"}), is an intronic variant that showed a borderline association in the overall (OR = 1.19, *P* = 4.78x10^--8^) and site-specific analyses \[OC (OR = 1.19, *P* = 1.65x10^--5^) and OPC (OR = 1.22, *P* = 4.26x10^--6^)\] ([Fig. 2c](#F2){ref-type="fig"}, [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). rs1453414 is upstream of *OR52N2,* an olfactory receptor, and within *TRIM5,* an E3-ubiquitin ligase, and is an eQTL for these genes in brain tissue[@R12] ([Supplementary Table 12](#SD14){ref-type="supplementary-material"}).

At 2p23.3, 4 SNPs showed evidence (*P* \< 5x10^--8^) for an association with OC, and in conditional analyses did not appear to be independent ([Supplementary Table 20](#SD14){ref-type="supplementary-material"}). These signals map to a high LD area that includes *C2orf16, ZNF512, CCDC121* and *GPN1* ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). The lead SNP, rs6547741, was associated with OC but not with OPC, and maps to an intron of *GPN1*, a GTPase involved in RNA polymerase II transport and DNA repair[@R13]. Associations between rs6547741 and OC were homogenous across other stratified analyses by region, sex, smoking and drinking status ([Fig. 3a](#F3){ref-type="fig"}).

Variation within 5p15.33 was also exclusively associated with OC (OPC, rs10462706, *P* = 0.47). The top signal, rs10462706, was associated with decreased OC risk (OR = 0.74, *P* = 5.54x10^--10^) and is in low LD (r^2^ = 0.15, [Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}) with the second strongest signal rs467095. These two variants are 7kb apart and map to intron 13 of *CLPTM1L* and in stratified analysis showed stronger effects in never smokers (*P*~het~ = 0.07 and *P*~het~ = 0.0028, respectively) and never drinkers (*P*~het~ = 0.01 and *P*~het~ = 0.0025, respectively) ([Fig. 3b](#F3){ref-type="fig"}, [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}). Conditional analyses showed that these SNPs are not completely independent ([Supplementary Table 21](#SD14){ref-type="supplementary-material"}). *TERT* and *CLPTM1L* encode the telomerase reverse transcriptase (*TERT*) and the cleft-lip and palate-associated transmembrane 1-like protein (*CLPTM1L*), respectively. Notably, rs467095 is an esophageal *TERT* eQTL[@R14] ([Supplementary Table 12](#SD14){ref-type="supplementary-material"}) and is in high LD with rs401681 (OR = 1.18, *P* = 2.1x10^--7^, r^2^ = 0.94) a widely studied SNP associated with risk of several cancers including: lung[@R15],[@R16], bladder, prostate, cervical, melanoma[@R17], basal cell[@R18], esophageal[@R19], pancreatic[@R20] and nasopharyngeal cancer[@R21]. Multiple 5p15.33 variants have been reported to independently influence cancer risk in both an increasing and decreasing fashion. Interestingly, rs401681\[A\] was associated with an increased OC risk similar to previous melanoma associations, and in an opposite direction to previous lung cancer results[@R17].

Several variants within the *CDKN2A--CDKN2B* locus (9p21.3) were found to be associated with OC. The lead SNP, rs8181047, is an intronic variant within the CDKN2B1 antisense RNA 1 (*CDKN2B-AS1*) ([Fig. 3c](#F3){ref-type="fig"}). rs8181047 is in LD (r^2^~range~ = 0.6-0.8) with 4 other 9p21.3 variants strongly associated with OC ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}) that in conditional analyses did not show independent associations ([Supplementary Table 22](#SD14){ref-type="supplementary-material"}). The *CDKN2A--CDKN2B* locus contains genes involved in cell-cycle regulation and senescence and has been associated with multiple malignancies including melanoma[@R22], glioma[@R23], basal cell[@R18], breast[@R24], lung[@R25], nasopharyngeal[@R26] and esophageal cancer[@R27]. Notably, *CDKN2A* is frequently mutated in HPV-negative head and neck cancers[@R28].

The OC associated variants at 9q34.12 mapped to an intron of *LAMC3,* a laminin involved in cortical development[@R29]. rs928674, the peak signal, showed consistent effects across strata and a weaker association with OPC (*P* = 0.003) ([Fig. 3d](#F3){ref-type="fig"}). rs928674 is in high LD with 3 other robustly associated 9q34.12 SNPs (r^2^~range~ = 0.82--0.96, [Supplemental Fig. 10](#SD1){ref-type="supplementary-material"}, [Supplementary Table 23](#SD14){ref-type="supplementary-material"}) and is an esophageal mucosa cis-eQTL for a downstream gene *AIF1L* (Allograft Inflammatory Factor 1-Like)[@R14].

The most prominent finding in the overall and OPC meta-analyses was a large association signal at 6p21.32 within the HLA class II region. The lead variant in both analyses, rs3828805, maps 1.7kb 5\' of *HLA-DQB1* ([Fig. 2d](#F2){ref-type="fig"} and [Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}) and similar to other 6p21.32 variants ([Supplementary Table 4](#SD8){ref-type="supplementary-material"} and [6](#SD10){ref-type="supplementary-material"}), showed heterogeneity by geographical region (*P*~het~ = 0.007) with no effect in South America (*P* = 0.62). Association analyses of 6p21.32 variants (*P* \< 5x10^--8^) conditioned on rs3828805 did not reveal multiple independent signals ([Supplementary Table 24](#SD5){ref-type="supplementary-material"}), suggesting a common haplotype. To further investigate HLA associations, we imputed classical alleles in 11,436 individuals (\>70% Caucasian ancestry) ([Online Methods](#S1){ref-type="sec"}). Three classical HLA alleles *DRB1\*1301*, *DQA1\*0103* and *DQB1\*0603* reached *P* \< 5x10^-8^ in the overall analysis and were also strongly associated with OPC ([Supplementary Table 25](#SD6){ref-type="supplementary-material"}). These alleles are in high LD (r^2^ \> 0.9) and are part of the HLA class II haplotype, *DRB1\*1301-DQA1\*0103-DQB1\*0603,* which is common in Europeans and previously reported to be associated with decreased cervical cancer risk[@R30]. *DRB1\*1301-DQA1\*0103-DQB1\*0603* was strongly associated with reduced OPC risk (OR = 0.59, *P* = 2.7x10^-9^) and more weakly with OC risk (OR = 0.75, *P* = 1.7x10^--4^). Further conditional analysis on this haplotype and 6p21.32 variants did not reveal evidence of additional independent effects ([Supplementary Table 26](#SD7){ref-type="supplementary-material"}). Given the importance of HPV infection in the etiology of cervical and oropharyngeal cancer[@R31], we conducted post-hoc analyses to examine the effect of *DRB1\*1301-DQA1\*0103-DQB1\*0603* in a subset of 576 cases with available HPV-status and 3,662 controls. *DRB1\*1301-DQA1\*0103-DQB1\*0603* was associated with a strong reduced risk of HPV-positive OPC (OR = 0.23, *P* = 1x10^-6^, n = 336) with no significant association in 240 OPC HPV-negative cases (OR = 0.75, *P* = 0.16) ([Table 3](#T3){ref-type="table"}). These results indicate that the class II HLA region is implicated in at least two HPV-driven cancers, namely HPV-positive OPC and cervical cancer. The lack of an association between 6p21.3 SNPs and OPC risk in South America could relate to previous findings that less than 10% of OPC are HPV-positive in this region[@R4],[@R5]. Moreover, a weaker association with OC could be due to a smaller proportion of these cases being HPV-positive, as well as possibly some misclassified OPC cases, especially for base of the tongue tumors. Further evaluation of the extent and specificity of this HLA effect in HPV-associated cancers is important given the strength of the observed association. This may help elucidate why some individuals are at higher risk of HPV-positive OPC after HPV infection and may also have implications for cancer immunotherapies targeting the HLA class II antigen presentation pathway[@R32].

In summary, we identified seven oral and pharyngeal cancer susceptibility loci including a strong HLA signal narrowed to a class II haplotype. Future replication of these findings in an independent population is warranted as well as fine-mapping and functional studies necessary to establish the biological framework underneath these associations.

Online Methods {#S1}
==============

Study population and genotyping {#S2}
-------------------------------

The study population comprised 6,034 cases and 6,585 controls derived from 12 epidemiological studies, the majority of case-control design and part of the International Head and Neck Cancer Epidemiology Consortium (INHANCE). Additionally, cases and controls from a European cohort study (EPIC) and cases from a United Kingdom case-series (HN5000) were also included. Characteristics and references for each study are summarized in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. Informed consent was obtained for all participants and studies were approved by respective Institutions Review Boards. Cancer cases comprised the following ICD codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9, C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9), overlapping (C14 and combination of other sites) and 25 oral or pharyngeal cases with unknown ICD code (other).

Genomic DNA isolated from blood or buccal cells was genotyped at the Center for Inherited Disease Research (CIDR) with a novel genotyping tool, the Illumina OncoArray custom designed for cancer studies by the OncoArray Consortium[@R33] part of the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network. The majority of the samples were genotyped as part of the oral and pharynx cancer OncoArray, with the exception of 2,476 shared controls (1,453 from the EPIC study and 1,023 from the Toronto study) that were genotyped at CIDR but as part of the Lung OncoArray. Genotype calls were made by the Dartmouth team in GenomeStudio software (Illumina, Inc.) using a standardized cluster file for OncoArray studies. Cluster plots for top SNPs for individuals genotyped as part the oral and pharynx cancer OncoArray are shown in [Supplementary Figure 12](#SD1){ref-type="supplementary-material"}.

GWAS quality control {#S3}
--------------------

We used PLINK 1.934 to conduct systematic quality-control (QC) steps on genotypes calls. An initial filtering step on the complete dataset excluded samples with genotyping rate \<80% and SNPs with call rate \<80%, then we excluded samples and SNPs \<95% call rates. During the individuals QC, we removed samples with unsolved genetic and reported sex discrepancies and individuals with outlying autosomic heterozygosity rate (+/-- 4 standard deviations (SD)). Identity-by-descent (IBD) analysis performed on the LD pruned dataset (r^2^ \< 0.1) identified; 103 expected experimental duplicate-pairs (IBD \> 0.9), from these we excluded the sample with lower genotyping rate, and 74 unexpected duplicate-pairs that were excluded. Additionally, we identified 44 unexpected relatives pairs (IBD \> 0.3) and excluded one sample from each pair, prioritizing cases over controls and for pairs with same status we excluded according to genotyping rate. After the initial SNP filtering calling rate and exclusion of duplicated and zeroed probes, 513,311 probes remained for analysis. Next and given the heterogeneity of the study population, we divided the dataset by geographical region (Europe, North America and South America) and excluded SNPs within each region with deviation of Hardy-Weinberg Equilibrium (HWE) in controls (*P* \< 1x10--7). To account for potential population stratification within geographical area, we performed principal components analysis (PCA) in EIGENSTRAT[@R35] using approximately 10,000 common markers in low LD (r^2^ \< 0.004, MAF \> 0.05), subsequently we excluded population outliers (n = 139) and derived regional eigenvectors to adjust regional GWAS analyses ([Supplementary Fig. 13](#SD1){ref-type="supplementary-material"}). PCA analyses on each individual study are displayed in [Supplementary Fig. 14](#SD1){ref-type="supplementary-material"}. To inquire about ancestry within regions, we used STRUCTURE 2.3.4[@R36] under a supervised approach with HapMap samples to determine individual CEU, YRI and CHB/JPT ancestries. All coordinates refer to genome build HG19/GRCh37.

Imputation {#S4}
----------

Imputation of unknown genetic variation was performed using the Michigan Imputation Server[@R37] (<https://imputationserver.sph.umich.edu/>), a free service for largescale population studies. We used SHAPEIT[@R38] for prephasing, Minimac3[@R39] for imputation and the first release of the Haplotype Reference Consortium panel[@R8] (HRC) a large collection of human haplotypes (n = 64,976) that combines data from multiple initiatives including the 1000 genomes project. For imputation we used a set of high-quality SNPs; MAF \> 0.01, call rate \>98%, we imputed in randomized batches of approximately 3000 individuals and analyzed imputation quality statistics together, SNPs with MAF \< 0.01 or R^2^ \< 0.3 in any of the batches were excluded before associations analysis. Thus, the final set of 7,099,472 imputed variants used in association analysis had very high quality: 86% of the variants with MAF ≥ 0.05 had R^2^ \> 0.9 and 52% of the less common variants (MAF \< 0.05) had R^2^ \> 0.9 ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

GWAS and meta-analyses {#S5}
----------------------

We undertook a by geographic region GWAS and meta-analysis approach to evaluate the relation between SNPs and overall OC and pharynx cancer, and site-specific OC and OPC risk; in total we tested we evaluated 7,574,753 SNPs (genotyped and imputed variants). By region GWAS were performed in PLINK and R glm function for genotype dosages, using multivariable unconditional logistic regression assuming a log-additive genetic or dosage model with age, sex and principal components as covariates. Next, association statistics were included in a fixed-effects meta-analysis performed in PLINK[@R34]. The *P*-value for heterogeneity was calculated using Cochran's Q. Conditional analyses within associated regions were performed in R (glm) and meta-analysis of regional results were done in PLINK.

HLA imputation and haplotype analyses {#S6}
-------------------------------------

Using SNP2HLA[@R40] and the Type I Diabetes Genetics Consortium reference panel of 5,225 individuals of European descent, we imputed HLA classical alleles and aminoacids in 11,436 study participants with \>70% CEU ancestry. Individuals were randomized into 12 groups approximately of 1000 each and quality imputation scores from beagle examined across groups. Markers with R^2^ \>= 0.7 in all groups and average R^2^ \> 0.9 (8,286 makers of 8,961 included in the panel) were carried on for analyses and 98% of these had R^2^ \> 0.95. We then performed regional association analyses of binary markers followed by meta-analysis of imputed binary markers (SNPs, classical alleles and aminoacids) as previously described using PLINK and R. DRB1\*1301-DQA1\*0103-DQB1\*0603 haplotype information was extracted from beagle files of phased best-guess genotypes and used to estimate ORs and 95%CIs from multivariable unconditional logistic regression models with each phenotype. Haplotype and HPV stratified analyses in a subset of cases with available data, was performed with unconditional logistic regression with haplotype as predictor and oropharyngeal cancer HPV positive or negative as outcomes. The measure of HPV positivity was derived by HPV16E6 serology in the ARCAGE and EPIC studies, tumor HPV16 DNA and p16 overexpression in the CHANCE study and for the Pittsburgh cases a combination of tumor HPV in situ hybridization and p16 immunohistochemistry.

Technical validation genotyping {#S7}
-------------------------------

In order to confirm array genotypes and imputed dosages, we genotyped at least one SNP within each associated (*P* \< 5x10--7) genomic region using TaqMan assays (Thermo Fisher Scientific) in a subset of approximately 900 individuals from ARCAGE, IARC Latin America, EPIC, and IARC oral cancer studies ([Supplementary Table 14](#SD14){ref-type="supplementary-material"}). Taqman genotyping included standard positive and negative controls; assay numbers and cycling conditions are described in [Supplementary Table 15](#SD14){ref-type="supplementary-material"}. For 10 of the 12 SNPs genotyped by TaqMan there was no evident departure from Hardy-Weinberg equilibrium (*P* \> 0.05). However, two variants rs467095 and rs3731239 were slightly out of HWE only in samples from the EPIC study (*P* \< 0.01), which might relate to the small sample size genotyped in the technical validation. The rare variants at 5p14.3 (rs79767424) and 10q26.13 (rs201982221, [Supplementary Figure 15](#SD1){ref-type="supplementary-material"}) could not be genotyped with TaqMan assays, thus for these, validation was performed with Sanger sequencing on the on a small subset of samples available within IARC studies; rs201982221 (15 wild-type, 15 heterozygous and 2 homozygous) and for rs79767424 (15 wild-type and 15 heterozygous). Primer sequences and conditions for PCR are described in [Supplementary Table 16](#SD14){ref-type="supplementary-material"}; amplification products were sequenced on the Applied Biosystems 3730 DNA Analyzer at Biofidal, France.

Bioinformatic annotation and analyses {#S8}
-------------------------------------

To explore possible functional implications of variants within associated regions, we used an internet tool HaploReg v4.1[@R41] that includes annotations from the Encyclopedia of DNA elements (ENCODE). Functional annotation for variants reaching *P* \< 5 x 10-8 is summarized [Supplemental Table 11](#SD4){ref-type="supplementary-material"}. We also retrieved eQTL information from several sources including the Genotype-Tissue Expression Project (GTEx)[@R14] and HaploReg[@R41]. Manhattan and quantile-quantile plots were generated in R using the package qqman[@R42], and forest plots were generated using the metafor R library[@R43]. Regional association plots were generated using LocusZoom[@R44] with LD and recombination rates data from the 1000 Genomes Project November 2014 release. To search for additional, pairwise LD information we used the online tool LD link[@R45].
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(a)4q23, rs1229984 (b)10q26.13, rs20198222 (c)11p15.4 rs1453414. (d)6p21.32 rs3828805. EAF = effect allele frequency in 6585 controls. Effect allele in square brackets. OC = oral cancer; OPC = oropharynx cancer.](emss-69808-f002){#F2}

![Forest plots of odds ratios for the lead SNP at each genome-wide significant loci in the oral cancer (OC) meta-analysis.\
(a)2p23.3 rs6547741 (b)5p15.33, rs10462706 (c)9p21.3, rs8181047 (d)9q34.12, rs928674. EAF = effect allele frequency in 6585 controls. Effect allele in square brackets. Overall = oral and pharyngeal cancer; OPC = oropharynx cancer.](emss-69808-f003){#F3}

###### 

Epidemiological and clinical characteristics of cases and controls.

                          Cases           Controls   
  ----------------------- ------- ------- ---------- -------
  **Total**               6,034           6,585      
  **Tumor site**                                     
  Oral cavity             2,990   49.6               
  Oropharynx              2,641   43.8               
  Hypopharynx             305     5.1                
  Overlapping             73      1.2                
  Other                   25      0.4                
  **Geographic Region**                              
  Europe                  2,499   41.4    2,928      44.5
  North America           2,549   42.2    2,522      38.3
  South America           986     16.3    1,135      17.2
  **Sex**                                            
  Male                    4,527   75.02   4,325      65.68
  Female                  1,507   24.98   2,260      34.32
  **Age, years**                                     
  =\<50                   1,315   21.8    1,355      20.6
  50-\<60                 2,006   33.2    1,954      29.7
  60-\<70                 1,748   29.0    1,983      30.1
  \>=70                   964     16.0    1,293      19.6
  Unknown                 1       0.02               
  **Smoking Status**                                 
  Never                   1,057   17.5    2,508      38.1
  Former                  1,792   29.7    2,263      34.4
  Current                 2,623   43.5    1,466      22.3
  Unknown                 562     9.3     348        5.3
  **Drinking Status**                                
  Never                   820     13.6    1,199      18.2
  Ever                    4,840   80.2    4,840      73.5
  Unknown                 374     6.2     546        8.3

###### 

Lead genome-wide significant SNP for each validated locus from the regional meta-analyses of oral and pharyngeal cancers combined and analysis of each cancer separately[a](#TFN1){ref-type="table-fn"} and pharynx cancer combined, as well as OC[a](#TFN1){ref-type="table-fn"} and OPC[a](#TFN1){ref-type="table-fn"} separately.

  Region                           SNP           chr:pos[b](#TFN2){ref-type="table-fn"}   Gene             EA/OA[c](#TFN3){ref-type="table-fn"}   Info (Rsq)[d](#TFN4){ref-type="table-fn"}   AF[e](#TFN5){ref-type="table-fn"} case/control   OR     *P*             *P* ~het~
  -------------------------------- ------------- ---------------------------------------- ---------------- -------------------------------------- ------------------------------------------- ------------------------------------------------ ------ --------------- -----------
  **Oral and pharyngeal cancer**                                                                                                                                                                                                                                      
  4q23                             rs1229984     4:100239319                              *ADH1B*          A/G                                    Geno                                        0.03/0.06                                        0.56   2.29x10^--15^   0.002
  6p21.32                          rs3828805     6:32636120                               *HLA-DQB1*       C/T                                    0.88                                        0.75/0.72                                        1.28   3.35x10^--13^   0.007
  10q26.13                         rs201982221   10:126157446                             *LHPP*           D/I                                    Geno                                        0.03/0.02                                        1.67   1.58x10^--9^    0.50
  11p15.4                          rs1453414     11:5829084                               *OR52N2/TRIM5*   C/A                                    Geno                                        0.23/0.20                                        1.19   4.78x10^--8^    0.55
  **Oral cancer**                                                                                                                                                                                                                                                     
  2p23.3                           rs6547741     2:27855924                               *GPN1*           A/G                                    0.98                                        0.50/0.54                                        0.83   3.97x10^--8^    0.34
  4q23                             rs1229984     4:100239319                              *ADH1B*          A/G                                    Geno                                        0.03/0.06                                        0.57   1.09x10^--9^    0.02
  5p15.33                          rs10462706    5:1343794                                *CLPTM1L*        T/C                                    0.97                                        0.12/0.15                                        0.74   5.54x10^--10^   0.84
  9p21.3                           rs8181047     9:22064465                               *CDKN2B-AS1*     A/G                                    Geno                                        0.29/0.24                                        1.24   3.80x10^--9^    0.37
  9q34.12                          rs928674      9:133952024                              *LAMC3*          G/A                                    0.89                                        0.14/0.12                                        1.33   2.09x10^--8^    0.88
  **Oropharyngeal cancer**                                                                                                                                                                                                                                            
  4q23                             rs1229984     4:100239319                              *ADH1B*          A/G                                    Geno                                        0.02/0.06                                        0.55   8.53x10^--9^    0.05
  6p21.32                          rs3828805     6:32636120                               *HLA-DQB1*       C/T                                    0.88                                        0.75/0.72                                        1.37   2.21x10^--12^   0.07

OC=oral cancer, OPC=oropharyngeal cancer;

SNP position according to NCBI genome build 37 (Hg19);

EA=Effect allele; OA=other allele;

Geno=genotyped, SNP, INFO, R^2^ is the average across imputation batches;

AF=allele frequency of the effect allele

###### 

Associations of *DRB1\*1301-DQA1\*0103-DQB1\*0603* haplotype in individuals with \>70% Caucasian ancestry

                                                                        Meta-analysis[c](#TFN8){ref-type="table-fn"}                                                       
  --------------------------------------------------------------------- ---------------------------------------------- --------------- ------ ------ ------ -------------- --
  **Oral and pharynx cancer**                                           0.68                                           3.32x10^--10^                                       
  Europe                                                                207/422                                        2,497/2,928     0.04   0.07   0.60   4.04x10^--8^   
  North America                                                         207/276                                        2,342/2,329     0.04   0.06   0.74   1.68x10^--3^   
  South America                                                         74/101                                         613/727         0.06   0.07   0.86   0.35           
                                                                                                                                                                           
  **Oral cancer**                                                       0.75                                           1.72x10^--4^                                        
  Europe                                                                106/422                                        1,231/2,928     0.04   0.07   0.60   1.52x10^--5^   
  North America                                                         128/276                                        1,135/2,329     0.06   0.06   0.92   4.67x10^--1^   
  South America                                                         41/101                                         351/727         0.06   0.07   0.80   0.26           
                                                                                                                                                                           
  **Oropharynx cancer**                                                 0.59                                           2.73x10^--9^                                        
  Europe                                                                84/422                                         1,098/2,928     0.04   0.07   0.57   2.69x10^--5^   
  North America                                                         72/276                                         1,119/2,329     0.03   0.06   0.52   3.49x10^--6^   
  South America                                                         31/101                                         216/727         0.07   0.07   1.05   0.81           
                                                                                                                                                                           
  **Oropharynx cancer by HPV status** [d](#TFN9){ref-type="table-fn"}                                                                                                      
  HPV-positive                                                          11/505                                         336/3,686       0.01   0.07   0.23   1.6x10^--6^    
  HPV-negative                                                          25/505                                         240/3,686       0.05   0.07   0.75   0.16           
                                                                                                                                                                           

Number of copies of the haplotype in cases and controls

Haplotype frequency calculated as total number of copies of haplotype in the population (haplotype copies/2n).

Fixed-effects meta-analysis of regional associations adjusted for age, sex and eigenvectors.

HPV-status available in a subset of cases from ARCAGE, EPIC, CHANCE and Pittsburgh studies

[^1]: deceased
